Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine in Children and Adolescents With ADHD
NCT05279313Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Treatment-Emergent Adverse Events at 136 weeks. Started Feb 2022; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05279313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279313.